Literature DB >> 19248098

Membrane type 1 matrix metalloproteinase is a crucial promoter of synovial invasion in human rheumatoid arthritis.

Mary-Clare Miller1, Hugh B Manning, Abhilash Jain, Linda Troeberg, Jayesh Dudhia, David Essex, Ann Sandison, Motoharu Seiki, Jagdeep Nanchahal, Hideaki Nagase, Yoshifumi Itoh.   

Abstract

OBJECTIVE: A hallmark of rheumatoid arthritis (RA) is invasion of the synovial pannus into cartilage, and this process requires degradation of the collagen matrix. The aim of this study was to explore the role of one of the collagen-degrading matrix metalloproteinases (MMPs), membrane type 1 MMP (MT1-MMP), in synovial pannus invasiveness.
METHODS: The expression and localization of MT1-MMP in human RA pannus were investigated by Western blot analysis of primary synovial cells and immunohistochemical analysis of RA joint specimens. The functional role of MT1-MMP was analyzed by 3-dimensional (3-D) collagen invasion assays and a cartilage invasion assay in the presence or absence of tissue inhibitor of metalloproteinases 1 (TIMP-1), TIMP-2, or GM6001. The effect of adenoviral expression of a dominant-negative MT1-MMP construct lacking a catalytic domain was also examined.
RESULTS: MT1-MMP was highly expressed at the pannus-cartilage junction in RA joints. Freshly isolated rheumatoid synovial tissue and isolated RA synovial fibroblasts invaded into a 3-D collagen matrix in an MT1-MMP-dependent manner. Invasion was blocked by TIMP-2 and GM6001 but not by TIMP-1. Invasion was also inhibited by the overexpression of a dominant-negative MT1-MMP, which inhibits collagenolytic activity and proMMP-2 activation by MT1-MMP on the cell surface. Synovial fibroblasts also invaded into cartilage in an MT1-MMP-dependent manner. This process was further enhanced by removing aggrecan from the cartilage matrix.
CONCLUSION: MT1-MMP serves as an essential collagen-degrading proteinase during pannus invasion in human RA. Specific inhibition of MT1-MMP-dependent invasion may represent a novel therapeutic strategy for RA.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19248098      PMCID: PMC2819053          DOI: 10.1002/art.24331

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  55 in total

Review 1.  Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry.

Authors:  Robert Visse; Hideaki Nagase
Journal:  Circ Res       Date:  2003-05-02       Impact factor: 17.367

2.  Membrane type I matrix metalloproteinase usurps tumor growth control imposed by the three-dimensional extracellular matrix.

Authors:  Kevin B Hotary; Edward D Allen; Peter C Brooks; Nabanita S Datta; Michael W Long; Stephen J Weiss
Journal:  Cell       Date:  2003-07-11       Impact factor: 41.582

Review 3.  Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned?

Authors:  M Feldmann; R N Maini
Journal:  Annu Rev Immunol       Date:  2001       Impact factor: 28.527

4.  Matrix metalloproteinases 1, 2, and 3 from rheumatoid synovial cells are sufficient to destroy joints.

Authors:  Y Okada; H Nagase; E D Harris
Journal:  J Rheumatol       Date:  1987-05       Impact factor: 4.666

5.  The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis.

Authors:  F C Arnett; S M Edworthy; D A Bloch; D J McShane; J F Fries; N S Cooper; L A Healey; S R Kaplan; M H Liang; H S Luthra
Journal:  Arthritis Rheum       Date:  1988-03

6.  Concanavalin A produces a matrix-degradative phenotype in human fibroblasts. Induction and endogenous activation of collagenase, 72-kDa gelatinase, and Pump-1 is accompanied by the suppression of the tissue inhibitor of matrix metalloproteinases.

Authors:  C M Overall; J Sodek
Journal:  J Biol Chem       Date:  1990-12-05       Impact factor: 5.157

7.  Oncostatin M in combination with tumor necrosis factor alpha induces cartilage damage and matrix metalloproteinase expression in vitro and in vivo.

Authors:  W Hui; A D Rowan; C D Richards; T E Cawston
Journal:  Arthritis Rheum       Date:  2003-12

8.  Aggrecan protects cartilage collagen from proteolytic cleavage.

Authors:  Michael A Pratta; Wenqing Yao; Carl Decicco; Micky D Tortorella; Riu-Qin Liu; Robert A Copeland; Ronald Magolda; Robert C Newton; James M Trzaskos; Elizabeth C Arner
Journal:  J Biol Chem       Date:  2003-07-30       Impact factor: 5.157

9.  Sequence-specific silencing of MT1-MMP expression suppresses tumor cell migration and invasion: importance of MT1-MMP as a therapeutic target for invasive tumors.

Authors:  Junko Ueda; Masahiro Kajita; Naoko Suenaga; Katsuyuki Fujii; Motoharu Seiki
Journal:  Oncogene       Date:  2003-11-27       Impact factor: 9.867

10.  Cleavage of syndecan-1 by membrane type matrix metalloproteinase-1 stimulates cell migration.

Authors:  Kazuhira Endo; Takahisa Takino; Hisashi Miyamori; Hidenori Kinsen; Tomokazu Yoshizaki; Mitsuru Furukawa; Hiroshi Sato
Journal:  J Biol Chem       Date:  2003-08-06       Impact factor: 5.157

View more
  53 in total

1.  The membrane tethered matrix metalloproteinase MT1-MMP triggers an outside-in DNA damage response that impacts chemo- and radiotherapy responses of breast cancer.

Authors:  Varsha Thakur; Keman Zhang; Alyssa Savadelis; Patrick Zmina; Brittany Aguila; Scott M Welford; Fadi Abdul-Karim; Kristen W Bonk; Ruth A Keri; Barbara Bedogni
Journal:  Cancer Lett       Date:  2018-11-29       Impact factor: 8.679

2.  Metalloproteinase binding proteins: WO2009097397.

Authors:  Yoshifumi Itoh
Journal:  Expert Opin Ther Pat       Date:  2010-08       Impact factor: 6.674

3.  Cherubism Mice Also Deficient in c-Fos Exhibit Inflammatory Bone Destruction Executed by Macrophages That Express MMP14 Despite the Absence of TRAP+ Osteoclasts.

Authors:  Mizuho Kittaka; Kotoe Mayahara; Tomoyuki Mukai; Tetsuya Yoshimoto; Teruhito Yoshitaka; Jeffrey P Gorski; Yasuyoshi Ueki
Journal:  J Bone Miner Res       Date:  2017-11-02       Impact factor: 6.741

4.  Implication of MMP-9 and urokinase plasminogen activator (uPA) in the activation of pro-matrix metalloproteinase (MMP)-13.

Authors:  Kyoung Soo Kim; Yeon-Ah Lee; Hyun Mi Choi; Myung Chul Yoo; Hyung-In Yang
Journal:  Rheumatol Int       Date:  2011-09-13       Impact factor: 2.631

5.  Modulation of matrix metalloproteinase production by rheumatoid arthritis synovial fibroblasts after cadherin 11 engagement.

Authors:  Erika H Noss; Sook Kyung Chang; Gerald F M Watts; Michael B Brenner
Journal:  Arthritis Rheum       Date:  2011-12

6.  New Strategies for the Next Generation of Matrix-Metalloproteinase Inhibitors: Selectively Targeting Membrane-Anchored MMPs with Therapeutic Antibodies.

Authors:  Laetitia Devy; Daniel T Dransfield
Journal:  Biochem Res Int       Date:  2010-10-28

7.  Role of cathepsin B in regulating migration and invasion of fibroblast-like synoviocytes into inflamed tissue from patients with rheumatoid arthritis.

Authors:  B Tong; B Wan; Z Wei; T Wang; P Zhao; Y Dou; Z Lv; Y Xia; Y Dai
Journal:  Clin Exp Immunol       Date:  2014-09       Impact factor: 4.330

8.  Matrix metalloproteinase 13 is a new contributor to skeletal muscle regeneration and critical for myoblast migration.

Authors:  Hanqin Lei; Dephne Leong; Lucas R Smith; Elisabeth R Barton
Journal:  Am J Physiol Cell Physiol       Date:  2013-06-12       Impact factor: 4.249

Review 9.  Restoring synovial homeostasis in rheumatoid arthritis by targeting fibroblast-like synoviocytes.

Authors:  Gyrid Nygaard; Gary S Firestein
Journal:  Nat Rev Rheumatol       Date:  2020-05-11       Impact factor: 20.543

Review 10.  Developments in the scientific understanding of rheumatoid arthritis.

Authors:  Jörg J Goronzy; Cornelia M Weyand
Journal:  Arthritis Res Ther       Date:  2009-10-14       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.